基于V型粉-烯基的聚烯复合物刺激GLP-1和PYY分泌,并改善小鼠的腹感
Yimei Zheng1, Tonglin Chen1, Ke Li1
1Guangdong Provincial Key Laboratory of Food Quality and Safety, College of Food Science, South China Agricultural University, 483 Wushan Road, Guangzhou 510642, China.
Carbohydrate polymers
|July 30, 2025
概括
像酸 (GA) 和酸 (TA) 这样的多与高氨糖玉米粉 (HAMS) 形成复合物. 这些HAMS-TA/GA复合物减少了粉消化,改善了血糖反应,并增强了小鼠的腹感,这表明功能性食物的潜力.
科学领域:
- 食品科学 食品科学 食品科学
- 营养科学 营养科学
- 生物化学 生化学
背景情况:
- 聚是具有潜在健康益处的植物化合物.
- 粉的消化能力会影响食后血糖反应.
- 高氨糖玉米粉 (HAMS) 具有独特的结构性质.
研究的目的:
- 为了研究酸 (GA) 或酸 (TA) 和HAMS.之间的复杂形成.
- 评估这些复合物对粉体内可消化的影响.
- 评估小鼠在体内对血糖反应,激素水平和腹感的影响.
主要方法:
- 通过非共价键,HAMS与GA和TA复合.
- 在体外消化试验测试以确定粉消化的速度 (k) 和可消化的比例 (C∞).
- 在小鼠体内研究以测量食后血糖反应,GLP-1和PYY度以及腹感.
主要成果:
- 在HAMS-TA中,HAMS-TA/GA复合体形成了V型晶体结构,在HAMS-TA中具有较高的多荷载.
- 由于结晶性增加和α-氨酶抑制,复合物体体内粉消化能力降低.
- 在体内研究显示,血糖反应较低,GLP-1和PYY水平升高,HAMS-TA/GA复合物,特别是HAMS-TA,增强了腹感.
结论:
- 粉-烯基基聚烯复合物,特别是HAMS-TA,显示出功能性食品开发的潜力.
- 这些复合物可以调节粉消化,血糖反应和腹感.
- 研究结果表明,通过饮食干预措施,可以应用于预防2型糖尿病和肥胖.
相关概念视频
01:24Glucagon-like Receptor Agonists
420
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
420
01:23Dipeptidyl Peptidase 4 Inhibitors
261
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
261
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
263
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
263
01:06Oral Hypoglycemic Agents: Glinides
263
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
263
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.4K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.4K